Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지

Preoperative Concurrent Radiochemotherapy for Locally Advanced Esophageal Cancer: Treatment Outcome and Prognostic Factors

국소 진행된 식도암에 대한 수술 전 동시병용 방사선-항암 화학요법: 치료 성적과 예후인자에 대한 연구

  • Kim, Hae-Young (Departments of Radiation Oncology, Sam sung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Kwan-Min (Departments of Thoracic Surgery, Sam sung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Jhin-Gook (Departments of Thoracic Surgery, Sam sung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Shim, Young-Mog (Departments of Thoracic Surgery, Sam sung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Im, Young-Hyuck (Departments of Medicine, Sam sung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Ahn, Yong-Chan (Departments of Radiation Oncology, Sam sung Medical Center, Sungkyunkwan University School of Medicine)
  • 김해영 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 김관민 (성균관대학교 의과대학 삼성서울병원 흉부외과) ;
  • 김진국 (성균관대학교 의과대학 삼성서울병원 흉부외과) ;
  • 심영목 (성균관대학교 의과대학 삼성서울병원 흉부외과) ;
  • 임영혁 (성균관대학교 의과대학 삼성서울병원 혈액종양내과) ;
  • 안용찬 (성균관대학교 의과대학 삼성서울병원 방사선종양학과)
  • Published : 2007.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: This study reports the results of the use of preoperative concurrent radiochemotherapy (CRCT) for the treatment of locoregionally advanced esophageal cancer. Materials and Methods: From 1998 through 2005, 61 patients with intrathoracic esophageal cancer at stages II-IVB (without distant organ metastasis and presumed to be respectable) received preoperative CRCT. CRCT consisted of radiotherapy (45 Gy /25 fractions /5 weeks) and FP chemotherapy (5-FU 1 g/$m^{2}$/day, days 1-4 and 29-32, Cisplatin 60 mg/$m^{2}$/day, days 1 and 29). An esophagectomy was planned in $4{\sim}6$ weeks after the completion of CRCT. Results: There were two treatment-related deaths. Among the 61 patients, 53 patients underwent surgery and 17 patients achieved a pathological complete response (pCR). The overall survival (OS) rates of all 61 patients at 2 and 5 years were 59.0% and 38.0%, respectively. The rates of OS and disease-free survival (DFS) of the surgically resected patients at 2 and 5 years were 61.6%, 40.1 % and 53.3%, 41.8%, respectively. By univariate analysis, achieviement of pCR and a clinically uninvolved distant lymph node (cMO) were favorable prognostic factors for OS and DFS. There were 27 patients that experienced a relapse-a locoregional relapse occurred in 5 patients, a distant metastasis occurred in 12 patients and combined failure occurred in 10 patients. Conclusion: The results of the current study are favorable. pCR and an uninvolved distant lymph node were found to be favorable prognostic factors.

목적 : 본 연구는 국소 진행된 식도암 환자들에 대하여 수술 전 동시병용 방사선-항암 화학요법을 적용한 치료 성적과 예후인자에 대해 알아보고자 하였다. 대상 및 방법: 1998년 3월부터 2005년 5월까지 삼성서울병원에서 식도암으로 진단 받고 수술 전 동시병용 방사선 항암화학요법을 적용한 환자는 모두 68명이었다. 이들 중 원발병변이 흉곽 내 식도에 위치하고, 조직형이 편평상피암이며 임상병기가 T3이상 또는 Nl이상 또는 혈행성 원격전이 없이 절제 가능한원격 림프절에 전이가 국한되어있는 M1A/B병기이며 다른 내과적 질환이나 이차암이 없는 61명의 환자들에 대해 분석을 시행하였다. 방사선치료는 임상 정사 등으로 확인된 병변에 대하여 5주 동안 45 Gy를 조사하였고, 항암화학요법은 2주기의 5-FU (1,000 $mg/m^{2}/day$, days 1-4 & 29-32)와 Cisplatin (60 $mg/m^{2}/day$, days l & 29)을 방사선치료와 동시에 병용하였다. 수술은 방사선-항암화학요법 종료 후 $4{\sim}6$주경에 계획하였으며 53명에 대해 lvor-Lewis 술기와 2-영역 혹은 3-영역 림프절 적출술을 시행하였다. 결과: 57명이 예정된 방사선-항암화학요법을 완료하였고(93.4%) 수술을 거부하거나 수술 전 방사선-항암화학요법 중 질병이 진행된 8명의 환자를 제외한 53명(86.8%)에서 식도 절제술을 시행하였는데, 이 중 49명(92.6%)에서 완전절제가 가능하였으며 38명(71.6%)에서 병기하강을 얻을 수 있었고, 17명(32.0%)에서 병리학적 완전 관해를 얻었다. 1명이 수술 후 호흡기 합병증으로, 1명이 방사선 병용 항암화학치료 연관 폐렴으로 사망하여 치료 연관 사망률은 3.2%였다. 전체 61명의 중앙 생존기간은 30개월, 2년 및 5년 생존율은 각각 59.0%와 38.0%였으며 수술을 시행 한 53명의 중앙 생존기간은 37개월, 2년 및 5년 생존율은 각각 61.6%와 40.1%없고, 중앙 무병 생존기간은 24개월, 2년 및 5년 무병생존율은 각각 53.3%와 41.8%였다. 전체 환자의 생존율에 영향을 미치는 예후인자는 수술 여부없으며 수술을 시행한 환자의 생존율이 단변량 분석(p=0.03)과 다변량 분석(p<0.01)에서 수술을 시행하지 않은 환자의 생존율에 비해 높았다. 수술을 시행한 환자를 대상으로 한 단변량 분석 결과 수술 전 임상병기가 IV병기가 아닌 경우, 수술 후 병리학적 완전관해를 얻은 경우 유의하게 생존율과 무병생존율이 높았으나 다변량 분석에서 의미 있는 예후인자는 없었다. 수술을 시행한 53명 중 5명(9.4%)에서 국소재발이, 10명(18.8%)에서 국소재발 및 원격전이가, 12명(22.6%)에서 원격전이가 발생하였다. 결론: 국소 진행된 병기의 식도암에서 수술 전 동시병용 방사선-항암화학요법으로 양호한 병기 하강률, 장기 생존율을 얻을 수 있었고 원격 림프절 전이가 없는 경우, 수술 후 병리학적 완전관해를 얻은 경우에서 높은 장기 생존율을 보였다.

Keywords

References

  1. Central Cancer Registry Center. Annual Report of the Central Cancer in Korea (2002.01-2002.12). 2003:11
  2. Muller JM, Erasmi H, Stelzner M, Zieren U, Pichlmaier H. Surgical therapy of oesophageal carcinoma. Br J Surg 1990;77:845-857 https://doi.org/10.1002/bjs.1800770804
  3. Lozac'h P, Topart P, Perramant M. Ivor Lewis procedure for epidermoid carcinoma of the esophagus. A series of 264 patients. Semin Surg Oncol 1997;13:238-244 https://doi.org/10.1002/(SICI)1098-2388(199707/08)13:4<238::AID-SSU4>3.0.CO;2-6
  4. Daly JM, Karnell LH, Menck HR. National Cancer Data Base report on esophageal carcinoma. Cancer 1996;78:1820-1828 https://doi.org/10.1002/(SICI)1097-0142(19961015)78:8<1820::AID-CNCR25>3.0.CO;2-Z
  5. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-313 https://doi.org/10.1200/JCO.2001.19.2.305
  6. Aisner J FA, Aroney R. Pattern of recurrence for cancer of the lung and esophagus. In: Wittes RE, ed. Cancer Treatment Symposia: Proceedings of the Workshop on Patterns of Failure after Cancer Treatment. US Department of Health and Human Services, 1983:87
  7. Kok TC LJ, Siersema PD. Neoadjuvant chemotherapy in operable esophageal squamous cell cancer: final report of a phase III multicenter randomized trial. Proc Am Soc Clin Oncol 1997;16:277a
  8. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727-1733 https://doi.org/10.1016/S0140-6736(02)08651-8
  9. Malthaner RA, Collin S, Fenlon D. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev 2006;3:CD001556
  10. Kaklamanos IG, Walker GR, Ferry K, Franceschi D, Livingstone AS. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a metaanalysis of randomized clinical trials. Ann Surg Oncol 2003; 10:754-761 https://doi.org/10.1245/ASO.2003.03.078
  11. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979-1984 https://doi.org/10.1056/NEJM199812313392704
  12. Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2002;183:274-279 https://doi.org/10.1016/S0002-9610(02)00795-X
  13. Gignoux M, Roussel A, Paillot B, et al. The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C. World J Surg 1987;11:426-432 https://doi.org/10.1007/BF01655805
  14. Wang M, Gu XZ, Yin WB, Huang GJ, Wang LJ, Zhang DW. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: report on 206 patients. Int J Radiat Oncol Biol Phys 1989;16:325-327 https://doi.org/10.1016/0360-3016(89)90323-4
  15. Greene FL PD, Fleming ID. AJCC cancer staging manual. 6th ed. Philadelphia, NW: Lippincott-Raven Co, 2002:113-123
  16. Cox JD SJ, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the Europeanorganization forresearch and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-1346 https://doi.org/10.1016/0360-3016(95)00060-C
  17. Hagen JA, DeMeester SR, Peters JH, Chandrasoma P, DeMeester TR. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg 2001;234:520-530 https://doi.org/10.1097/00000658-200110000-00011
  18. Hagen JA, DeMeester SR, Peters JH, Chandrasoma P, DeMeester TR. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg 2001;234:discussion 530-521
  19. Kelsen D. Preoperative chemoradiotherapy for esophageal cancer. J Clin Oncol 2001;19:283-285 https://doi.org/10.1200/JCO.2001.19.2.283
  20. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326:1593-1598 https://doi.org/10.1056/NEJM199206113262403
  21. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20:1167-1174
  22. Nam TK, Nah BS, Chung WK, Ahn SJ, Song JY. Results of concurrent chemoradiotherapy and intraluminal brachytherapy in esophageal carcinoma: retrospective analysis with respect to survival. J Korean Soc Ther Radiol Oncol 2004;22:25-32
  23. Leichman L, Steiger Z, Seydel HG, et al. Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: a potentially curative approach. J Clin Oncol 1984; 2:75-79 https://doi.org/10.1200/JCO.1984.2.2.75
  24. Geh JI, Crellin AM, Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg 2001;88:338-356 https://doi.org/10.1046/j.1365-2168.2001.01670.x
  25. Hironaka S, Ohtsu A, Boku N, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T (2-3) N (any) M (0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 2003; 57:425-433 https://doi.org/10.1016/S0360-3016(03)00585-6
  26. Poplin E, Fleming T, Leichman L, et al. Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-8037). J Clin Oncol 1987;5: 622-628 https://doi.org/10.1200/JCO.1987.5.4.622
  27. Heath EI, Burtness BA, Heitmiller RF, et al. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 2000;18:868-876 https://doi.org/10.1200/JCO.2000.18.4.868
  28. Bedenne L, Seitz JF, Milan C, et al. Cisplatin, 5-FU and preoperative radiotherapy in esophageal epidermoid cancer. Multicenter phase II FFCD 8804 study. Gastroenterol Clin Biol 1998;22:273-281
  29. Bates BA, Detterbeck FC, Bernard SA, Qaqish BF, Tepper JE. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J Clin Oncol 1996;14:156-163 https://doi.org/10.1200/JCO.1996.14.1.156
  30. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161-167 https://doi.org/10.1056/NEJM199707173370304
  31. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005;6:659-668 https://doi.org/10.1016/S1470-2045(05)70288-6
  32. Le Prise E, Etienne PL, Meunier B, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994;73:1779-1784 https://doi.org/10.1002/1097-0142(19940401)73:7<1779::AID-CNCR2820730702>3.0.CO;2-T
  33. Lee JL, Park SI, Kim SB, et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 2004;15: 947-954 https://doi.org/10.1093/annonc/mdh219
  34. Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992;16:1104-1109 https://doi.org/10.1007/BF02067069
  35. Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992;16:discussion 1110
  36. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335:462-467 https://doi.org/10.1056/NEJM199608153350702
  37. Kleinberg L, Knisely JP, Heitmiller R, et al. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2003;56:328-334 https://doi.org/10.1016/S0360-3016(02)04598-4
  38. Carlos AP LWEC, Rupert KS. Principles and practice of radiation oncology. Fourth ed; Lippincott Wlilliams & Wikins, 2004: 1287
  39. Liao Z, Zhang Z, Jin J, et al. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys 2004;60:1484-1493 https://doi.org/10.1016/j.ijrobp.2004.05.056
  40. Forastiere AA, Orringer MB, Perez-Tamayo C, Urba SG, Zahurak M. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol 1993;11:1118-1123 https://doi.org/10.1200/JCO.1993.11.6.1118